Empagliflozin vs Rituximab

## Empagliflozin vs Rituximab: Overview

This comparison examines the pharmacological differences between **Empagliflozin** and **Rituximab**.

## Mechanism of Action

**Empagliflozin**: Selective SGLT2 inhibitor reducing renal glucose reabsorption.

**Rituximab**: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

## Pharmacokinetics

**Half-life**: Empagliflozin — 12.4 hours; Rituximab — 22 days.

## Chemical Properties

**Molecular Formula**: Empagliflozin — C23H27ClO7; Rituximab — N/A.

**Molecular Weight**: Empagliflozin — 450.9100 g/mol; Rituximab — N/A.

**Type**: Empagliflozin — Small molecule; Rituximab — Antibody.